Progression-free survival (PFS) only moderately correlates with overall survival (OS) at the individual and trial level in patients with HER2-positive metastatic breast cancer treated with ...
Co-primary efficacy in RAS G12–mutant PDAC included statistically significant OS and PFS gains assessed by blinded ...
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...
DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet ...
SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...
Please provide your email address to receive an email when new articles are posted on . The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according ...
TAK-700 plus ADT improved responses and progression-free survival compared with bicalutamide plus ADT. TAK-700 plus androgen deprivation therapy (ADT) did not provide an overall survival (OS) benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results